Minervax
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $58M
Investors
- 7
About Minervax
Minervax ApS specializes in vaccine development aimed at preventing Group B Streptococcus infections.Minervax specializes in the clinical development of innovative vaccines, primarily targeting Group B Streptococcus (GBS) infections. Their core product, AlpN GBS, is a prophylactic vaccine designed for pregnant women and older adults, aiming to prevent adverse pregnancy outcomes and severe infections that can result from GBS. The vaccine is currently advancing towards Phase 3 clinical trials, indicating a commitment to addressing critical unmet medical needs in maternal and geriatric healthcare. Revenue is expected to primarily come from partnerships with healthcare institutions for the procurement of their vaccine, once regulatory approval is achieved. Their business model involves B2B transactions, collaborating with pharmaceutical distributors and healthcare providers to facilitate vaccine distribution, alongside contracts and grants that support ongoing research and clinical trials. The focus remains on advancing towards commercialization, with potential new products being designed to address additional health concerns.
Who invested in Minervax
7 investors across 1 round
See all investors in Minervax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 15, 2020
Amount
$58M
Investors
Questions about Minervax
Who invested in Minervax?
Minervax has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Minervax raised?
Minervax has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Minervax last raise money?
Minervax's most recent round on record is a Series B, in Dec 2020.
What does Minervax do?
Minervax ApS specializes in vaccine development aimed at preventing Group B Streptococcus infections.
Where is Minervax headquartered?
Minervax is headquartered in Copenhagen, Denmark.
Which VCs invest in companies like Minervax?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Minervax's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Minervax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.